A phase 1 clinical trial of a new cellular immunotherapy being developed in Australia for the treatment of multiple sclerosis (MS) has found that it improved symptoms and quality of life for the majority of patients. …
Latest Video
New Stories
-
Bridge Program participants visit US-based companies
December 12, 2018 - - Latest News -
TGA approves new Opdivo dosing schedule
December 12, 2018 - - Latest News -
Australia delivers world first for new cancer therapy
December 12, 2018 - - Latest News -
Exclusive: PBAC targets lung cancer in first pan-tumour outcome
December 11, 2018 - - Latest News -
Hitting a nerve on 'workplace flexibility'
December 11, 2018 - - Latest News -
Companies share their approach to workplace flexibility
December 11, 2018 - - Latest News -
Updated healthcare atlas highlights medicine use
December 11, 2018 - - Latest News